Old Web
English
Sign In
Acemap
>
Paper
>
Potential cancer risk with omalizumab? A disproportionality analysis of the WHO's VigiBase pharmacovigilance database.
Potential cancer risk with omalizumab? A disproportionality analysis of the WHO's VigiBase pharmacovigilance database.
2021
Diogo Mota
Tiago Azenha Rama
Milton Severo
André Moreira
Keywords:
Intensive care medicine
Omalizumab
Pharmacovigilance
cancer risk
MEDLINE
Medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
6
References
0
Citations
NaN
KQI
[]